JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products. Sonia T. Oskouei, PharmD, BCMAS, DPLA: All biosimilars ...

Adalimumab is prescribed to treat autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis ...

More than 90% of patients with inflammatory bowel disease (IBD) accepted the switch from the adalimumab reference product to adalimumab biosimilars, with favourable survival and remission outcomes and ...

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that ...

Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis. The ...

INCHEON, South Korea, May 23, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ® ...

Jan. 2, 2003 — Abbott Laboratories received U.S. Food and Drug Administration (FDA) approval this week to market adalimumab (Humira), previously known as D2E7. The drug was approved for the treatment ...

The appraisal committee considered evidence submitted by AbbVie and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of adalimumab for the treatment of psoriasis in adults, having considered evidence on the nature of the ...